Afuco™ Anti-CD200 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-210) (CAT#: AFC-TAB-210)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD200. It is a humanized monoclonal antibody designed for oncology indications.
Specific Inquiry
Custom Production
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.
We require custom production
Normal Tissue
RNA Expression
Figure 1 Cerebral cortex
(Glial cells
Staining: Medium
Intensity: Moderate
Quantity: 75%-25%
Location: Cytoplasmic/membranous
Neuronal cells
Staining: Medium
Intensity: Strong
Quantity: <25%
Location: Cytoplasmic/membranous
Neuropil
Staining: High
Intensity: Strong
Quantity:>75%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/31149/64346_B_7_5.jpg
(Glial cells
Staining: Medium
Intensity: Moderate
Quantity: 75%-25%
Location: Cytoplasmic/membranous
Neuronal cells
Staining: Medium
Intensity: Strong
Quantity: <25%
Location: Cytoplasmic/membranous
Neuropil
Staining: High
Intensity: Strong
Quantity:>75%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/31149/64346_B_7_5.jpg
Figure 2 Colon
(Peripheral nerve/ganglion
Staining: Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/31149/64346_A_9_3.jpg
(Peripheral nerve/ganglion
Staining: Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/31149/64346_A_9_3.jpg
Figure 3 Liver
(Cholangiocytes
Staining: Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/membranous nuclear)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/31149/64346_A_9_4.jpg
(Cholangiocytes
Staining: Medium
Intensity: Moderate
Quantity:>75%
Location: Cytoplasmic/membranous nuclear)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/31149/64346_A_9_4.jpg
Figure 4 Kidney
(Cells in tubules
Staining: High
Intensity: Strong
Quantity:>75%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/31149/64346_A_8_5.jpg
(Cells in tubules
Staining: High
Intensity: Strong
Quantity:>75%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/31149/64346_A_8_5.jpg
Figure 5 Testis
(Leydig cells
Staining: Medium
Intensity: Moderate
Quantity:>75%
Sertoli cells
Staining: Medium
Intensity: Moderate
Quantity: 75%-25%)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/31149/64346_A_5_6.jpg
(Leydig cells
Staining: Medium
Intensity: Moderate
Quantity:>75%
Sertoli cells
Staining: Medium
Intensity: Moderate
Quantity: 75%-25%)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/31149/64346_A_5_6.jpg
Figure 6 Lymph node
(Germinal center cells
Staining: Medium
Intensity: Moderate
Quantity: 75%-25%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/31149/64346_A_9_8.jpg
(Germinal center cells
Staining: Medium
Intensity: Moderate
Quantity: 75%-25%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/31149/64346_A_9_8.jpg
Figure 7 RNA cell line category: Cell line enhanced (AF22, HHSteC, NTERA-2, REH, SK-MEL-30, WM-115)
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000091972-CD200
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000091972-CD200
Figure 7 RNA cell line category: Cell line enhanced (AF22, HHSteC, NTERA-2, REH, SK-MEL-30, WM-115)
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000091972-CD200
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000091972-CD200
Specifications
- Immunogen
- The details of the immunogen for this antibody are not available.
- Host Species
- Human
- Derivation
- Humanized (from mouse)
- Type
- ADCC enhanced antibody
- Species Reactivity
- Human
- Applications
- IF, IP, Neut, FuncS, ELISA, FC
- Conjugate
- Unconjugated
- Generic Name
- Samalizumab
- Related Disease
- Blood cancers
Product Property
- Purity
- >95% by SDS-PAGE
- Storage
- Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
- Alternative Names
- Anti-CD200; CD200; CD200 molecule; antigen identified by monoclonal MRC OX 2, CD200 antigen, MOX1, MOX2; OX-2 membrane glycoprotein; MRC; OX 2; CD200 antigen; MRC OX-2 antigen; antigen identified by monoclonal MRC OX-2; MOX1;
- Gene ID
- 4345
- UniProt ID
- P41217
Related Resources
Please refer to Samalizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Samalizumab.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Samalizumab"
DrugMonitor™ Anti-Samalizumab Antibody (VS-1224-YC1057)Samalizumab has been used in trials studying the treatment of multiple myeloma and B-cell chronic lymphocytic leukemia. The DrugMonitor™ Anti-Samalizumab Antibody (VS-1224-YC1057) is an anti-drug antibody (ADA) against Samalizumab. This drug-based antibody is raised in mice immunized with the Samalizumab. The anti-Samalizumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Samalizumab in samples.
See other products for "CD200"
Select a product category from the dropdown menu below to view related products.
Please select product type
IgG Antibody Products
Humanized Antibody Products
Neutralizing Antibody Products
Blocking Antibody Products
Rabbit Monoclonal Antibody Products
ScFv Antibody Products
Fab Antibody Products
ScFv-Fc Chimera Products
Extracellular Vesicle (EV) Antibody Products
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOB-1205z | Mouse Anti-CD200 Recombinant Antibody (clone 20C7) | FC, IHC, FuncS | Mouse IgG1 |
| MOB-2283MZ | Mouse Anti-CD200 Recombinant Antibody (clone NSD PY-3) | FC | Mouse IgG1 |
| VS3-XY233 | Mouse Anti-CD200 Recombinant Antibody (clone 1D4C11) | ELISA, WB | Mouse IgG2a |
| VS3-XY234 | Mouse Anti-CD200 Recombinant Antibody (clone 6E8B11) | ELISA, WB | Mouse IgG2a |
| VS-0723-WK246 | Rabbit Anti-CD200 Recombinant Antibody (VS-0723-WK246) | ELISA, FC | Rabbit IgG |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for AFC-TAB-210. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: ELISA, IHC
Application: FuncS, IF, Neut, ELISA, FC, IP, ICC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: ELISA, Inhib, FC, Neut
Application: ELISA, IHC, IF, IP
Application: ELISA, WB, IF, FC, IP
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
